{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:27:28Z","timestamp":1794565648579,"version":"4.9.1"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013806","name":"Shenyang Pharmaceutical University","doi-asserted-by":"publisher","award":["YQ202202"],"award-info":[{"award-number":["YQ202202"]}],"id":[{"id":"10.13039\/501100013806","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973528"],"award-info":[{"award-number":["81973528"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273821"],"award-info":[{"award-number":["82273821"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872766"],"award-info":[{"award-number":["81872766"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005047","name":"Liaoning Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2025-MS-266"],"award-info":[{"award-number":["2025-MS-266"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005047","name":"Liaoning Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2025-MSLH-636"],"award-info":[{"award-number":["2025-MSLH-636"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejmech.2026.118998","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T23:57:02Z","timestamp":1780012622000},"page":"118998","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design, synthesis, and biological evaluation of novel ICA-II derivatives as anti-hepatocellular carcinoma agents targeting EGFR"],"prefix":"10.1016","volume":"316","author":[{"given":"Wenlong","family":"Kou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiulin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjiao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingbo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-2467","authenticated-orcid":false,"given":"Shaojiang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejmech.2026.118998_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118998_bib2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118998_bib3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2026.118998_bib4","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejmech.2026.118998_bib5","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"SHARP investigators study group. Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118998_bib6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41392-020-0187-x","article-title":"The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects","volume":"5","author":"Tang","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118998_bib7","article-title":"Targeting STARD4\/EGFR axis inhibits growth and overcomes Lenvatinib resistance in hepatocellular carcinoma","volume":"12","author":"Liu","year":"2025","journal-title":"Genes Dis."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118998_bib8","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1021\/acs.jnatprod.9b01285","article-title":"Natural products as sources of new drugs over the nearly four decades from 01\/1981 to 09\/2019","volume":"83","author":"Newman","year":"2020","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.ejmech.2026.118998_bib9","article-title":"Astragalus injection alleviates diabetic cognitive impairment (DCI) through dual effects of anti-neuroinflammation and antioxidative stress based on network pharmacology analysis and experimental validation","author":"Tong","year":"2026","journal-title":"Acupuncture and Herbal Medicine"},{"issue":"3","key":"10.1016\/j.ejmech.2026.118998_bib10","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jep.2011.01.001","article-title":"The genus epimedium: an ethnopharmacological and phytochemical review","volume":"134","author":"Ma","year":"2011","journal-title":"J. Ethnopharmacol."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118998_bib11","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1111\/cas.14641","article-title":"Icaritin-induced immunomodulatory efficacy in advanced hepatitis B virus-related hepatocellular carcinoma: immunodynamic biomarkers and overall survival","volume":"111","author":"Qin","year":"2020","journal-title":"Cancer Sci."},{"issue":"12","key":"10.1016\/j.ejmech.2026.118998_bib12","doi-asserted-by":"crossref","first-page":"21274","DOI":"10.3390\/molecules201219763","article-title":"Comparative pharmacokinetics study of icariin and icariside II in rats","volume":"20","author":"Cheng","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.118998_bib13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.freeradbiomed.2025.10.266","article-title":"Icariside II induces ferroptosis and apoptosis by activating oxidative stress for non-small-cell lung cancer therapy","volume":"242","author":"Jiang","year":"2026","journal-title":"Free Radic. Biol. Med."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118998_bib14","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/ddr.21967","article-title":"Icariside II suppresses the tumorigenesis and development of ovarian cancer by regulating miR-144-3p\/IGF2R axis","volume":"83","author":"Yuan","year":"2022","journal-title":"Drug Dev. Res."},{"issue":"24","key":"10.1016\/j.ejmech.2026.118998_bib15","doi-asserted-by":"crossref","first-page":"10257","DOI":"10.1021\/jm501100b","article-title":"Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals","volume":"57","author":"Vitaku","year":"2014","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.ejmech.2026.118998_bib16","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1016\/j.tetlet.2014.11.046","article-title":"Nature loves nitrogen heterocycles","volume":"56","author":"Walsh","year":"2015","journal-title":"Tetrahedron Lett."},{"issue":"12","key":"10.1016\/j.ejmech.2026.118998_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.arabjc.2021.103449","article-title":"2-Methylindole analogs as cholinesterases and glutathione S-Transferase inhibitors: synthesis, biological evaluation, molecular docking, and pharmacokinetic studies","volume":"14","author":"Cetin","year":"2021","journal-title":"Arab. J. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118998_bib18","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ijc.34512","article-title":"Proxalutamide in metastatic castration-resistant prostate cancer: primary analysis of a multicenter, randomized, open-label, phase 2 trial","volume":"153","author":"Zhou","year":"2023","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.118998_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2022.08.025","article-title":"Proxalutamide in patients with AR-Positive metastatic breast cancer: results from an open-label multicentre phase Ib study and biomarker analysis","volume":"176","author":"Jiang","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"8","key":"10.1016\/j.ejmech.2026.118998_bib20","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1016\/j.bmc.2013.02.008","article-title":"Novel 1,3,4-Oxadiazole thioether derivatives targeting thymidylate synthase as dual anticancer\/antimicrobial agents","volume":"21","author":"Du","year":"2013","journal-title":"Bioorg. Med. Chem."},{"issue":"18","key":"10.1016\/j.ejmech.2026.118998_bib21","doi-asserted-by":"crossref","first-page":"13172","DOI":"10.1021\/acs.jmedchem.3c01141","article-title":"Discovery and crystallography study of novel biphenyl ether and oxadiazole thioether (Non-Arylmethylamine)-based small-molecule PD-1\/PD-L1 inhibitors as immunotherapeutic agents","volume":"66","author":"Liu","year":"2023","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118998_bib22","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1007\/s00044-022-02913-y","article-title":"Synthesis and antitumor activity evaluation in vitro of 4-Aminoquinazoline derivatives containing 1,3,4-Thiadiazole","volume":"31","author":"Si","year":"2022","journal-title":"Med. Chem. Res."},{"issue":"17","key":"10.1016\/j.ejmech.2026.118998_bib23","doi-asserted-by":"crossref","first-page":"12373","DOI":"10.1021\/acs.jmedchem.3c00863","article-title":"Discovery, optimization, and evaluation of novel N-(Benzimidazol-5-Yl)-1,3,4-Thiadiazol-2-Amine analogues as potent STAT3 inhibitors for cancer treatment","volume":"66","author":"Wang","year":"2023","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118998_bib24","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1021\/acs.jnatprod.2c00908","article-title":"Synthesis and structure\u2013activity analysis of icaritin derivatives as potential tumor growth inhibitors of hepatocellular carcinoma cells","volume":"86","author":"Li","year":"2023","journal-title":"J. Nat. Prod."},{"issue":"18","key":"10.1016\/j.ejmech.2026.118998_bib25","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.1021\/ol302031z","article-title":"Catalyst-free intramolecular oxidative cyclization of N-Allylbenzamides: a new route to 2,5-Substituted oxazoles","volume":"14","author":"Zhou","year":"2012","journal-title":"Org. Lett."},{"issue":"14","key":"10.1016\/j.ejmech.2026.118998_bib26","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1081\/SCC-200025582","article-title":"Microwave-assisted one-step synthesis of substituted 2-Chloromethyl-1,3,4-Oxadiazoles","volume":"34","author":"Natero","year":"2004","journal-title":"Synth. Commun."},{"key":"10.1016\/j.ejmech.2026.118998_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106147","article-title":"Novel 5,6-Diphenyl-1,2,4-Triazine-3-Thiol derivatives as dual COX-2\/5-LOX inhibitors devoid of cardiotoxicity","volume":"129","author":"Saraf","year":"2022","journal-title":"Bioorg. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118998_bib28","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.3390\/ijms21062235","article-title":"Synthesis, anticancer evaluation and structure-activity analysis of novel (E)- 5-(2-Arylvinyl)-1,3,4-Oxadiazol-2-Yl)Benzenesulfonamides","volume":"21","author":"Szafra\u0144ski","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118998_bib29","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ejmech.2018.12.069","article-title":"Discovery of first-in-class thiazole-based dual FFA1\/PPAR\u03b4 agonists as potential anti-diabetic agents","volume":"164","author":"Li","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118998_bib30","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1021\/jf047985e","article-title":"Antifeedant activity, and QSAR analysis of new Oxa(Thia)Diazolyl 3(2H)-Pyridazinones","volume":"53","author":"Cao","year":"2005","journal-title":"J. Agric. Food Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118998_bib31","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev., Dis. Primers"},{"key":"10.1016\/j.ejmech.2026.118998_bib32","unstructured":"Icaritin-induced immunomodulatory efficacy in advanced hepatitis B virus-related hepatocellular carcinoma: immunodynamic biomarkers and overall survival - qin - 2020 - cancer science - wiley online library. https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cas.14641 (accessed 2026-February-1)."},{"key":"10.1016\/j.ejmech.2026.118998_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110013","article-title":"Icariside II suppresses cervical cancer cell migration through JNK modulated matrix Metalloproteinase-2\/9 inhibition in vitro and in vivo","volume":"125","author":"Sun","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118998_bib34","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13065-019-0531-9","article-title":"A comprehensive review on biological activities of oxazole derivatives","volume":"13","author":"Kakkar","year":"2019","journal-title":"BMC Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118998_bib35","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jhep.2012.02.019","article-title":"Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells","volume":"57","author":"Eggelpo\u00ebl","year":"2012","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118998_bib36","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jhep.2004.08.024","article-title":"Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma","volume":"41","author":"H\u00f6pfner","year":"2004","journal-title":"J. Hepatol."},{"issue":"10","key":"10.1016\/j.ejmech.2026.118998_bib37","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.3390\/cancers11101588","article-title":"Calcium regulates HCC proliferation as well as EGFR recycling\/degradation and could be a new therapeutic target in HCC","volume":"11","author":"Modica","year":"2019","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118998_bib38","doi-asserted-by":"crossref","first-page":"915","DOI":"10.18632\/oncotarget.13687","article-title":"Non-toxic dose of liposomal honokiol suppresses metastasis of hepatocellular carcinoma through destabilizing EGFR and inhibiting the downstream pathways","volume":"8","author":"Yang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2026.118998_bib39","first-page":"1","article-title":"Hepatitis B virus-encoded X protein downregulates EGFR expression via inducing MicroRNA-7 in hepatocellular carcinoma cells","volume":"2013","author":"Chen","year":"2013","journal-title":"Evid.-Based Complement. Altern. Med."},{"key":"10.1016\/j.ejmech.2026.118998_bib40","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.canlet.2018.11.006","article-title":"YTHDF2 suppresses cell proliferation and growth via destabilizing the EGFR mRNA in hepatocellular carcinoma","volume":"442","author":"Zhong","year":"2019","journal-title":"Cancer Lett."},{"issue":"52","key":"10.1016\/j.ejmech.2026.118998_bib41","doi-asserted-by":"crossref","first-page":"40183","DOI":"10.1074\/jbc.M607958200","article-title":"Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations","volume":"281","author":"Perez-Torres","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2026.118998_bib42","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/2159-8290.CD-14-0326","article-title":"Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations","volume":"4","author":"Janjigian","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2026.118998_bib43","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.canlet.2018.10.029","article-title":"Primate-specific miR-944 activates P53-Dependent tumor suppression in human colorectal cancers","volume":"441\u2013441","author":"Kim","year":"2019","journal-title":"Cancer Lett."},{"issue":"18","key":"10.1016\/j.ejmech.2026.118998_bib44","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.3390\/cancers13184504","article-title":"Erlotinib promotes ligand-induced EGFR degradation in 3D but not 2D cultures of pancreatic ductal adenocarcinoma cells","volume":"13","author":"Betriu","year":"2021","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.ejmech.2026.118998_bib45","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1159\/000499765","article-title":"Systemic treatment options in hepatocellular carcinoma","volume":"8","author":"Rimassa","year":"2019","journal-title":"Liver Cancer"},{"issue":"6","key":"10.1016\/j.ejmech.2026.118998_bib46","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.tibs.2011.03.006","article-title":"The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation","volume":"36","author":"Mendoza","year":"2011","journal-title":"Trends Biochem. Sci."},{"issue":"20","key":"10.1016\/j.ejmech.2026.118998_bib47","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"W1","key":"10.1016\/j.ejmech.2026.118998_bib48","doi-asserted-by":"crossref","first-page":"W357","DOI":"10.1093\/nar\/gkz382","article-title":"SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules","volume":"47","author":"Daina","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"Web Server issue","key":"10.1016\/j.ejmech.2026.118998_bib49","doi-asserted-by":"crossref","first-page":"W26","DOI":"10.1093\/nar\/gku477","article-title":"Update on drug classification and target prediction","volume":"42","author":"Nickel","year":"2014","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118998_bib50","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nbt1284","article-title":"Relating protein pharmacology by Ligand chemistry","volume":"25","author":"Keiser","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejmech.2026.118998_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/cpbi.5","article-title":"The GeneCards suite: from gene data mining to disease genome sequence analyses","volume":"54","author":"Stelzer","year":"2016","journal-title":"Curr. Protoc. Bioinform."},{"issue":"D1","key":"10.1016\/j.ejmech.2026.118998_bib52","doi-asserted-by":"crossref","first-page":"D1302","DOI":"10.1093\/nar\/gkaa1027","article-title":"Open targets platform: supporting systematic drug-target identification and prioritisation","volume":"49","author":"Ochoa","year":"2021","journal-title":"Nucleic Acids Res."},{"issue":"D1","key":"10.1016\/j.ejmech.2026.118998_bib53","doi-asserted-by":"crossref","first-page":"D1038","DOI":"10.1093\/nar\/gky1151","article-title":"Org: leveraging knowledge across phenotype-gene relationships","volume":"47","author":"Amberger","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"D1","key":"10.1016\/j.ejmech.2026.118998_bib54","doi-asserted-by":"crossref","first-page":"D1398","DOI":"10.1093\/nar\/gkab953","article-title":"Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents","volume":"50","author":"Zhou","year":"2022","journal-title":"Nucleic Acids Res."},{"issue":"D1","key":"10.1016\/j.ejmech.2026.118998_bib55","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"issue":"D1","key":"10.1016\/j.ejmech.2026.118998_bib56","doi-asserted-by":"crossref","first-page":"D605","DOI":"10.1093\/nar\/gkaa1074","article-title":"The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene\/measurement sets","volume":"49","author":"Szklarczyk","year":"2021","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118998_bib57","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":"A software environment for integrated models of biomolecular interaction networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res."},{"issue":"W1","key":"10.1016\/j.ejmech.2026.118998_bib58","doi-asserted-by":"crossref","first-page":"W216","DOI":"10.1093\/nar\/gkac194","article-title":"DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update)","volume":"50","author":"Sherman","year":"2022","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118998_bib59","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The protein data bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2026.118998_bib60","series-title":"The Pymol Molecular Graphics System, Version 2.5; (Publisher)","author":"Schr\u00f6dinger","year":"2021"},{"issue":"7","key":"10.1016\/j.ejmech.2026.118998_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1005659","article-title":"OpenMM 7: rapid development of high performance algorithms for molecular dynamics","volume":"13","author":"Eastman","year":"2017","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.ejmech.2026.118998_bib62","unstructured":"Avogadro - SBGrid consortium - supported software. https:\/\/sbgrid.org\/software\/titles\/avogadro (accessed 2026-April-26)."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118998_bib63","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","article-title":"AutoDock Vina 1.2.0: new docking methods, expanded force field, and python bindings","volume":"61","author":"Eberhardt","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.118998_bib64","series-title":"BIOVIA, Dassault Syst\u00e8mes. Discovery Studio Visualizer, V21.1.0; 20298","year":"2021"},{"key":"10.1016\/j.ejmech.2026.118998_bib65","series-title":"Amber 2024 Reference Manual","author":"Case","year":"2024"},{"issue":"9","key":"10.1016\/j.ejmech.2026.118998_bib67","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jcc.20035","article-title":"Development and testing of a general amber force field","volume":"25","author":"Wang","year":"2004","journal-title":"J. Comput. Chem."},{"issue":"16","key":"10.1016\/j.ejmech.2026.118998_bib68","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/jcc.10128","article-title":"Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation","volume":"23","author":"Jakalian","year":"2002","journal-title":"J. Comput. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118998_bib69","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","article-title":"ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB","volume":"11","author":"Maier","year":"2015","journal-title":"J. Chem. Theor. Comput."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118998_bib70","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1021\/acs.chemrestox.9b00030","article-title":"Binding modes and metabolism of caffeine","volume":"32","author":"Jandova","year":"2019","journal-title":"Chem. Res. Toxicol."},{"issue":"10","key":"10.1016\/j.ejmech.2026.118998_bib71","doi-asserted-by":"crossref","DOI":"10.1063\/1.2464095","article-title":"Langevin stabilization of molecular-dynamics simulations of polymers by means of quasisymplectic algorithms","volume":"126","author":"Larini","year":"2007","journal-title":"J. Chem. Phys."},{"issue":"12","key":"10.1016\/j.ejmech.2026.118998_bib72","doi-asserted-by":"crossref","first-page":"10089","DOI":"10.1063\/1.464397","article-title":"Particle mesh Ewald: An N\u22c5log(N) method for Ewald sums in large systems","volume":"98","author":"Darden","year":"1993","journal-title":"J. Chem. Phys."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118998_bib73","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0021-9991(77)90098-5","article-title":"Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-Alkanes","volume":"23","author":"Ryckaert","year":"1977","journal-title":"J. Comput. Phys."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118998_bib74","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1021\/ct400341p","article-title":"Cheatham TE 3rd. PTRAJ and CPPTRAJ: Software for processing and analysis of molecular dynamics Trajectory Data","volume":"9","author":"Roe","year":"2013","journal-title":"J. Chem. Theory Comput."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118998_bib75","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/jcc.21372","article-title":"Fast and accurate predictions of binding free energies using MM-PBSA and MM-GBSA","volume":"31","author":"Rastelli","year":"2010","journal-title":"J. Comput. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118998_bib76","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1021\/ci100275a","article-title":"Assessing the performance of the MM\/PBSA and MM\/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations","volume":"51","author":"Hou","year":"2010","journal-title":"J. Chem. Inf. Model."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118998_bib77","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","article-title":"The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities","volume":"10","author":"Genheden","year":"2015","journal-title":"Expert Opin. Drug Discov."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118998_bib78","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1021\/ct3010485","article-title":"Improved generalized born solvent model parameters for protein simulations","volume":"9","author":"Nguyen","year":"2013","journal-title":"J. Chem. Theor. Comput."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118998_bib79","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1021\/j100058a043","article-title":"Accurate calculation of hydration free energies using macroscopic solvent models","volume":"98","author":"Sitkoff","year":"1994","journal-title":"J. Phys. Chem."},{"key":"10.1016\/j.ejmech.2026.118998_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.797821","article-title":"Discovery of small molecule NSC290956 as a therapeutic agent for KRas mutant non-small-cell lung cancer","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118998_bib82","unstructured":"Quantitative Proteomics Using Formalin-Fixed Paraffin-Embedded Tissues of Oral Squamous Cell Carcinoma."},{"key":"10.1016\/j.ejmech.2026.118998_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2025.111814","article-title":"Novel senescence inducer ICA-11c, a derivative of icaritin, YAP-dependently suppresses hepatocellular carcinoma cells","volume":"423","author":"Chen","year":"2026","journal-title":"Chem. Biol. Interact."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426004435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426004435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:04:25Z","timestamp":1794564265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426004435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":81,"alternative-id":["S0223523426004435"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118998","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and biological evaluation of novel ICA-II derivatives as anti-hepatocellular carcinoma agents targeting EGFR","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118998","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118998"}}